Advertisement

Neurological Sciences

, Volume 40, Issue 7, pp 1377–1382 | Cite as

Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer’s disease patients: a retrospective observational study

  • Eugenia Scaricamazza
  • Isabella Colonna
  • Giulia Maria Sancesario
  • Francesca Assogna
  • Maria Donata Orfei
  • Flaminia Franchini
  • Giuseppe Sancesario
  • Nicola Biagio Mercuri
  • Claudio LiguoriEmail author
Original Article

Abstract

Alzheimer’s disease (AD) is the most common form of dementia characterized by the prevalent memory impairment. Mild cognitive impairment (MCI) may represent the early stage of AD, in particular when MCI patients show biomarkers consistent with AD pathology (MCI due to AD). Neuropsychiatric symptoms (NPS) frequently affect both MCI and AD patients. Cerebrospinal-fluid (CSF) tau and β-amyloid42 (Aβ42) levels are actually considered the most sensitive and specific biomarkers for AD neurodegeneration. In the present retrospective observational study, we evaluated CSF biomarkers and neuropsychological data (also including NPS measured by the neuropsychiatric inventory—NPI) in a population of patients affected by MCI due to AD compared with mild to moderate AD patients. We documented higher NPI scores in MCI compared with AD patients. In particular, sub-items related to sleep, appetite, irritability, depression, and anxiety were higher in MCI than AD. We also found the significant correlation between NPS and CSF AD biomarkers in the whole population of MCI and AD patients. Consistently, t-tau/Aβ42 ratio correlated with NPS in all the MCI and AD patients. These results suggest the more prevalent occurrence of NPS in MCI patients showing AD pathology and converting to dementia than AD patients. Moreover, a more significant degree of AD neurodegeneration, featured by high t-tau/Aβ42 ratio, correlated with more severe NPS, thus supposing that in MCI and AD patients a more extensive AD neurodegeneration is related to more severe behavioral disturbances.

Keywords

Neuropsychiatric symptoms Cognitive impairment CSF biomarkers Mild cognitive impairment Alzheimer’s disease 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Mega MS, Cummings JL, Fiorello T, Gornbein J (1996) The spectrum of behavioral changes in AD. Neurology 46(1):130–135CrossRefPubMedGoogle Scholar
  2. 2.
    Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, Brashear R, Miller DS (2011) Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement 7(5):532–539CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Del Prete M, Spaccavento S, Craca A, Fiore P, Angelelli P (2009) Neuropsychiatric symptoms and the APOE genotype in Alzheimer’s disease. Neurol Sci 30(5):367–373CrossRefPubMedGoogle Scholar
  4. 4.
    Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO (2006) Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67(9):1575–1580CrossRefPubMedGoogle Scholar
  5. 5.
    Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, Hägerström D, Jögi J, Smith R, Schöll M (2017) Tau pathology distribution in Alzheimer’s disease corresponds differentially to cognition-relevant functional brain networks. Front Neurosci 11:167CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, Riekkinen P, Soininen H (1997) The level of CSF tau correlates with neurofibrillary tangles in AD. Neurol Rep 8(18):3961–3963Google Scholar
  7. 7.
    Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, Teipel SJ, Graz C, Blennow K, Hampel H (2005) Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 65(9):1502–1503CrossRefPubMedGoogle Scholar
  8. 8.
    Brys PE, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ (2007) Prediction and longitudinal study of CSF biomarkers in MCI. Neurobiol Aging 30(5):682–690CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D, Blankenstein MA, Scheltens P, van der Flier WM (2014) The CSF AD profile: easily said, but what does it mean? Alzheimers Dement 10(6):713–723CrossRefPubMedGoogle Scholar
  10. 10.
    Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient AD disease in patients with MCI: a follow-up study. Lancet Neurol 5(3):228–234CrossRefPubMedGoogle Scholar
  11. 11.
    Chung JA, Cummings JL (2000) Neurobehavioral and neuropsychiatric symptoms in Alzheimer’s disease: characteristics and treatment. Neurol Clin 18(4):829–846CrossRefPubMedGoogle Scholar
  12. 12.
    Yazar T, Yazar HO, Demir EY, Özdemir F, Çankaya S, Enginyurt Ö (2018) Assessment of the mental health of carers according to the stage of patients with diagnosis of Alzheimer-type dementia. Neurol Sci 39(5):903–908CrossRefPubMedGoogle Scholar
  13. 13.
    Ballarini T, Iaccarino L, Magnani G, Ayakta N, Miller BL, Jagust WJ, Gorno-Tempini ML, Rabinovici GD, Perani D (2016) Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset AD. Hum Brain Mapp 37(12):4234–4247CrossRefPubMedGoogle Scholar
  14. 14.
    Ng KP, Pascoal TA, Mathotaarachchi S, Chung CO, Benedet AL, Shin M, Kang MS, Li X, Ba M, Kandiah N, Rosa-Neto P, Gauthier S (2017) Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology 88(19):1814–1821CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Skogseth R, Mulugeta E, Jones E, Ballard C, Rongve A, Nore S, Alves G, Aarsland D (2008) Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer’s disease. Dement Geriatr Cogn Disord 25(6):559–563CrossRefPubMedGoogle Scholar
  16. 16.
    Ramakers IH, Verhey FR, Scheltens P, Hampel H, Soininen H, Aalten P, Rikkert MO, Verbeek MM, Spiru L, Blennow K, Trojanowski JQ, Shaw LM, Visser PJ (2013) Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 43(5):911–920CrossRefPubMedGoogle Scholar
  17. 17.
    Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TL, Fagan AM, Morris JC, Roe CM (2016) Mood changes in cognitively normal older adults are linked to Alzheimer’s disease biomarker levels. Am J Geriatr Psychiatry 24(11):1095–1104CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:270e279CrossRefGoogle Scholar
  19. 19.
    Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CRJ (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74:199e208Google Scholar
  20. 20.
    McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7(3):263–269CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cummings JL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 48:S10–S16CrossRefPubMedGoogle Scholar
  22. 22.
    Liguori C, Romigi A, Mercuri NB, Nuccetelli M, Izzi F, Albanese M, Sancesario G, Martorana A, Sancesario GM, Bernardini S, Marciani MG, Placidi F (2014) Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. J Neurol 261(9):1832–1836CrossRefPubMedGoogle Scholar
  23. 23.
    Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 288(12):1475–1483CrossRefGoogle Scholar
  24. 24.
    Spalletta G, Long JD, Robinson RG, Trequattrini A, Pizzoli S, Caltagirone C, Orfei MD (2015) Longitudinal neuropsychiatric predictors of death in Alzheimer’s disease. J Alzheimers Dis 48(3):627–636CrossRefPubMedGoogle Scholar
  25. 25.
    Chen CT, Chang CC, Chang WN, Tsai NW, Huang CC, Chang YT, Wang HC, Kung CT, Su YJ, Lin WC, Cheng BC, Su CM, Hsiao SY, Hsu CW, Lu CH (2017) Neuropsychiatric symptoms in Alzheimer’s disease: associations with caregiver burden and treatment outcomes. QJM 110:565–570CrossRefPubMedGoogle Scholar
  26. 26.
    Okonkwo OC, Alosco ML, Griffith HR, Mielke MM, Shaw LM, Trojanowski JQ, Tremont G (2010) Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease. Arch Neurol 67(6):688–696CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Binetti G, Mega MS, Magni E, Padovani A, Rozzini L, Bianchetti A, Trabucchi M, Cummings JL (1998) Behavioral disorders in Alzheimer disease: a transcultural perspective. Arch Neurol 55:539–544CrossRefPubMedGoogle Scholar
  28. 28.
    Albrecht D, Pendergrass A, Becker C, Hautzinger M, Pfeiffer K (2018) Interventionsstudien zur Unterstützung häuslicher Pflege. Z Gerontol Geriatr 51:642–649CrossRefPubMedGoogle Scholar
  29. 29.
    Chiotis K, Saint-Aubert L, Savitcheva I, Jelic V, Andersen P, Jonasson M, Eriksson J, Lubberink M, Almkvist O, Wall A, Antoni G, Nordberg A (2016) Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm. Eur J Nucl Med Mol Imaging 43(9):1686–1699CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Defrancesco M, Marksteiner J, Kemmler G, Fleischhacker WW, Blasko I, Deisenhammer EA (2017) Severity of depression impacts imminent conversion from mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis 59:1439–1448CrossRefPubMedGoogle Scholar
  31. 31.
    Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D (2006) Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 63(5):530–538CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Teng E, Lu PH, Cummings JL (2007) Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to AD. Dement Geriatr Cogn Disord 24(4):253–259CrossRefPubMedGoogle Scholar
  33. 33.
    Sinforiani E, Terzaghi M, Pasotti C, Zucchella C, Zambrelli E, Manni R (2007) Hallucinations and sleep-wake cycle in Alzheimer’s disease: a questionnaire-based study in 218 patients. Neurol Sci 28(2):96–99CrossRefPubMedGoogle Scholar
  34. 34.
    Liguori C, Nuccetelli M, Izzi F, Sancesario G, Romigi A, Martorana A, Amoroso C, Bernardini S, Marciani MG, Mercuri NB, Placidi F (2016) Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer’s disease. Neurobiol Aging 40:120–126CrossRefPubMedGoogle Scholar
  35. 35.
    Tekin S, Mega MS, Masterman DM, Chow T, Garakian J, Vinters HV, Cummings JL (2001) Orbitofrontal and anterior cingulate cortex neurofibrillary tangyle burden is associated with agitation in Alzheimer disease. Ann Neurol 49(3):355–361CrossRefPubMedGoogle Scholar
  36. 36.
    Zubenko GS, Moossy J, Martinez AJ, Rao G, Claassen D, Rosen J, Kopp U (1991) Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 48(6):619–624CrossRefPubMedGoogle Scholar
  37. 37.
    Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA (1995) The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer’s disease. J Neuropsychiatr Clin Neurosci 7(4):476–484CrossRefGoogle Scholar
  38. 38.
    Steenland K, Zhao L, Goldstein F, Cellar J, Lah J (2014) Biomarkers for predicting cognitive decline in those with normal cognition. J Alzheimers Dis 40(3):587–594CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2019

Authors and Affiliations

  • Eugenia Scaricamazza
    • 1
  • Isabella Colonna
    • 2
  • Giulia Maria Sancesario
    • 3
  • Francesca Assogna
    • 4
    • 5
  • Maria Donata Orfei
    • 5
  • Flaminia Franchini
    • 1
    • 5
  • Giuseppe Sancesario
    • 1
  • Nicola Biagio Mercuri
    • 1
    • 5
  • Claudio Liguori
    • 1
    Email author
  1. 1.Neurology Unit, Department of Systems MedicineUniversity of Rome “Tor Vergata”RomeItaly
  2. 2.Department of NeurologyMedical University of GrazGrazAustria
  3. 3.Clinical and Behavioral NeurologySanta Lucia FoundationRomeItaly
  4. 4.Centro Fermi - Museo Storico della Fisica e Centro Studi e Ricerche “Enrico Fermi”RomeItaly
  5. 5.IRCSS Fondazione Santa LuciaRomeItaly

Personalised recommendations